Xiaoyun Zhang

Xiaoyun Zhang

Auto-generated profile, based on publicly available information

Xiaoyun Zhang

Weifang Key Laboratory of Basic Research on Chronic Diseases and Stem Cell Therapy, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong, PR China.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
JYJie Yu
Jie Yu
XCXinghui Cui
Xinghui Cui
XZXiaoyun Zhang
Xiaoyun Zhang
MCMin Cheng
Min Cheng
XCXiaodong Cui
Xiaodong Cui
Pyroptosis is a new type of pro-inflammatory programmed cell death identified over the last few years and has since attracted researchers' attention. Current research demonstrates that pyroptosis's primary process is dependent on caspase-1 protein and gasdermin D protein and is accompanied by the release of inflammatory substances. However, the specific mechanisms and physiological or pathophysiological processes involved in pyroptosis are unclear. Presently, research on the occurrence, development, and treatment of various diseases associated with pyroptosis is of significant value. Pyroptosis has been implicated in the pathogenesis of atherosclerosis. For instance, numerous studies have revealed that pyroptosis is involved in the development and progression of atherosclerosis, and it is closely associated with pyroptosis of three essential cells (vascular endothelial cells, macrophages, and vascular smooth muscle cells) in atherosclerosis. The advancement of research on pyroptosis is anticipated to give insights into its application as a potential method for treating diseases. This article mainly reviews the relationship between pyroptosis and associated mechanisms factors that cause pyroptosis and the relationship between pyroptosis and various diseases, especially atherosclerosis.

10 December 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
WXWenchao Xu
Wenchao Xu
JLJie Li
Jie Li
JJJie Ju
Jie Ju
MLMin Liu
Min Liu
WWWenxu Wang
Wenxu Wang
HCHao Chen
Hao Chen
Beta1-adrenergic receptor (β 1 -AR) belongs to G protein-coupled receptors, regulating cardiac physiological and pathological process through complex signaling pathways. Physiologically, the activation of β 1 -AR produces positive chronotropic, positive inotropic and positive dromotropic effects in the heart. However, excessive or sustained activation of β 1 -AR can cause myocardial injury, arrhythmias, and heart failure. The β 1 -AR in the heart exhibits tissue-specific distribution patterns and subcellular localization features adapted to its function within cardiomyocytes. Upon ligand binding, the β 1 -AR undergoes conformational changes and transmits signaling through G protein-dependent pathways (β 1 -AR/Gs and β 1 -AR/Gi) as well as a G protein-independent pathway (β 1 -AR/β-arrestin) to regulate cardiac activity. Subsequently, the β 1 -AR can either dissociate from G protein to undergo desensitization and terminate signal transduction, or it can be endocytosed into the cell, transported to the lysosome to be degraded, or returned to the plasma membrane to continue its function. Additionally, it has been found that β 1 -AR can cause or exacerbate heart disease when abnormal changes occur in its distribution density, localization, and mediated downstream signaling pathways. Therefore, β 1 -AR represents an important pharmacotherapeutic target for the treatment of cardiac diseases. Among the relevant therapeutic agents, β 1 -AR blockers designed specifically against β 1 -AR have evolved to the third generation. This review comprehensively analyzes β 1 -AR from perspectives including its research history, expression, and distribution in the heart, protein structure, signaling pathways, and associations with cardiac diseases.

10 March 2026 in Cell Death Discovery
Verified
Journal Article
Open access
JLJie Li
Jie Li
WXWenchao Xu
Wenchao Xu
JJJie Ju
Jie Ju
MLMin Liu
Min Liu
WWWenxu Wang
Wenxu Wang
HCHao Chen
Hao Chen
Atherosclerosis constitutes the primary pathological basis for cardiovascular diseases. It most commonly develops at the branching and curved regions of blood vessels. The disturbed blood flow in these regions can generate oscillatory shear stress (OSS). Endothelial cells exposed to OSS progressively undergo a transformation into mesenchymal cells, a process known as endothelial-to-mesenchymal transition (EndMT). EndMT is a critical event in the development of atherosclerosis. OSS promotes the occurrence of EndMT through multiple pathways. This paper provides a comprehensive analysis of the phenomena and mechanisms of OSS-induced EndMT, offering theoretical insights into the pathogenic mechanisms of atherosclerosis and corresponding therapeutic strategies.

24 September 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
JZJunhui Zhao
Junhui Zhao
XZXiaoyun Zhang
Xiaoyun Zhang
YWYanhui Wang
Yanhui Wang
YZYu Zeng
Yu Zeng
HSHongliang Sun
Hongliang Sun
XCXiaodong Cui
Xiaodong Cui
Mesenchymal stem cells (MSCs) are widely utilized in tissue repair, anti-inflammatory treatment, and cell therapy due to their remarkable multidirectional differentiation potential, immunosuppressive capabilities, and low immunogenicity. However, the regulatory mechanisms underlying their functions are intricate, and epigenetic modifications are a significant contributing factor. N6-methyladenosine (m6A) modification affects the proliferation, differentiation, and immunomodulation of MSCs by regulating the stability, transport, and translation of RNA. Studies have shown that m6A modification promotes osteogenic differentiation through the bone morphogehetic protein/small mothers against decapentaplegic (BMP/Smad) and wingless-related integration site/β-catenin (Wnt/β-catenin) pathways. It also enhances the anti-inflammatory effect of MSCs by modulating immune cell polarization and the release of inflammatory mediators. Moreover, exosomes secreted by MSCs contribute to immunomodulation and the response to cancer treatment by regulating the m6A modification of genes in target cells. “Writers” of m6A, such as methyltransferase-like 3 (METTL3) and METTL14, and “erasers”, such as fat mass and obesity-associated protein (FTO) and alkB homolog 5 (ALKBH5), are crucial in regulating the functions of MSCs. Targeting m6A modification via the clinical application of MSCs may represent a new cancer treatment strategy. Therefore, a comprehensive investigation of the m6A regulatory mechanism is essential. This review provides theoretical and technical support for the clinical use of MSCs, facilitating the development of more effective therapeutic strategies.